Innovation

Inven2 are responsible for assessing and commercialising innovative research conducted at the University of Oslo, Oslo University Hospital and the health trusts under the South-Eastern Norway Regional Health Authority.

Since the establishment of Inven2 13 years ago, we have contributed to the establishment of 71 companies and 428licenses alongside innovative researchers. This has led to NOK 773 million being channelled back to research and innovation.

Innovation motivated by patients

Jan Terje Andersen learnt about laboratory work when he was studying to become a biomedical laboratory scientist. Scientific curiosity led him to the Department of Biosciences at the University of Oslo.

A lecture by Professor Inger Sandlie decided his future career. Today, he is one of the researchers with the most innovations at Inven2.

Portfolio businesses

Portfolio businesses

Inven2 has a portfolio comprising 50 companies. We have established them either on our own or alongside investors and others. The point of departure for the companies are research results from innovative researchers. The portfolio value in December 2023 is NOK 11 billion, but this will vary with the value of the individual company and how long we are shareholders in the most valuable companies.

Products on the market

Products on the market

Inven2 has contributed to many products and services that have served society well through licensing to industry or business start-ups within a range of technology fields. What follows is a selection of them.

Latest innovation news

Latest innovation news

These are news about Inven2’s new and ongoing innovation projects, companies we have been a contributed part in establishing, new products and services on the market and other relevant news regarding innovation.
Summary of the year 2023

Summary of the year 2023

Inven2 is grateful to everyone who has contributed to building business and helping patients through new inventions, clarification, clinical...

read more